RxDoctor Payments Data

John Serfas, MD

Interventional Cardiology · Kansas City, KSNPI 1508203761

Payments from drug & device makers

What this record shows

This record is dominated by grants: $26,433 of the $30,708 with a category attached, or 86.1%. Medtronic accounts for 68.8% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2021 at $23,835 and has fallen 98.4% since, to $392 in 2025.

$30,708in general payments, 2019–2025

Across 68 payments — averaging $451.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$21K
  • Abbott$7K
  • Edwards Lifesciences$1K
  • Boston Scientific$169
  • W. L. Gore & Associates, Inc.$165
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$149
  • plus $906 from 18 others

What the payments were for

  • Grants$26,43386%
  • Travel & lodging$6452%
  • Food & beverage$3,62912%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,708 in reported general payments places this provider in the 85th percentile of 55 interventional cardiology providers in Kansas.

See all interventional cardiology providers in Kansas

Medicare billing

Part B allowed, 2024
$83,364
Medicare patients
424
Services billed
1,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin48$51,388
EliquisApixaban25$26,809
WegovySemaglutide13$19,908
Metoprolol Succinate71$907
Midodrine Hcl12$553
Spironolactone53$498
Atorvastatin Calcium36$484
Warfarin Sodium27$349
Losartan Potassium31$313
Potassium Chloride16$231
Ezetimibe12$136
Furosemide20$118
Amlodipine Besylate25$94
Carvedilol22$93
Torsemide11$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$19$51,38848 claims
PfizerEliquis$50$26,80925 claims
Novo NordiskWegovy$80$19,90813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 55 interventional cardiology providers in Kansas.

Other interventional cardiology in Kansas City

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →